Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +217.77%
#3 ONFA ONFA +54.06%
#4 Metaplex Metaplex +23.53%
#5 Wrapped Krown Wrapped Krown +20.08%
#6 Osaka Protocol Osaka Protocol +18.53%
#7 Talus Network Talus Network +17.86%
#8 DODO DODO +17.35%
#9 Magma Finance Magma Finance +15.62%
#10 Black Phoenix Black Phoenix +15.03%
Coin of the day
DeFiChain DeFiChain
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Kedudukan dalam Saham #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Harga Saham
$0.94180721
Modal Pasaran
$22.26M
Perubahan (1 hari)
0.38%
Perubahan (1 tahun)
-14.35%
Negara
FR
Perdagangan Valbiotis SA (ALVAL)

Kategori

Healthcare
Pendapatan untuk Valbiotis SA (ALVAL)
Pendapatan pada Dec 2025 TTM: $-11.05M
Menurut laporan kewangan terkini Valbiotis SA, pendapatan semasa syarikat ialah $-11.05M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-10.39M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-15.24M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Valbiotis SA dari 2015 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-11.05M 6.26%
2024 $-10.40M 0.09%
2023 $-10.39M -31.83%
2022 $-15.24M 28.45%
2021 $-11.86M 91.50%
2020 $-6.19M -17.90%
2019 $-7.54M 32.17%
2018 $-5.71M 94.72%
2017 $-2.93M 369.81%
2016 $-623.95K -40.51%
2015 $-1.05M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$24.72B -223,839.46%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.17B -46,859.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.16B -46,779.37%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,450.04%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.48B -13,505.47%
NL